We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR

By LabMedica International staff writers
Posted on 08 Apr 2026

GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. More...

The collaboration is designed to let clinicians at interested health systems order the test at the point of care, receive results, and manage follow-up within native EHR workflows. The integration is expected to enable approximately 450 health systems to deliver Galleri results within their existing patient portals, aiming to reduce administrative burden and manual processes while improving provider and patient experience.

Galleri is a proactive screening tool performed from a simple blood draw and is described as capable of detecting more than 50 cancer types before symptoms appear. The assay is supported by GRAIL’s targeted methylation-based platform and provides a cancer signal of origin prediction with high accuracy to guide diagnostic work-up when a signal is detected. It is described as the only available MCED test with demonstrated performance in patients screened for cancer. The test requires a prescription and is intended to complement, not replace, recommended screenings; it is recommended for adults with an elevated risk for cancer, such as those aged 50 years and older.

Implementation planning began in the first quarter of 2026 with initial integrations and early adopter programs. GRAIL is working with Epic and Amazon Web Services (AWS) to support workflow alignment, training, and deployment, with broad availability expected by the end of 2026.

“Today, recommended screening exists for only five cancers in the U.S., yet more than 70% of deaths are caused by cancers without a recommended screening test. With a scalable integration through Epic, we are reducing operational barriers and making it easier for healthcare providers to incorporate the Galleri test into routine care, with the ultimate goal of supporting early cancer detection before symptoms appear, when outcomes may be better,” said Josh Ofman, MD, MSHS, President at GRAIL.

“Aura helps healthcare organizations collaborate by removing administrative barriers. With GRAIL joining the Epic community, together with healthcare organizations, we can advance early detection and ultimately improve cancer survival rates,” said Alan Hutchison, Vice President at Epic.


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.